PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRomosozumab
Evenity(romosozumab)
Evenity (romosozumab) is an antibody pharmaceutical. Romosozumab was first approved as Evenity on 2019-04-09. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis. The pharmaceutical is active against sclerostin.
Download report
Favorite
FDA Novel Drug Approvals 2019
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Evenity
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Romosozumab
Tradename
Proper name
Company
Number
Date
Products
Evenityromosozumab-aqqgAmgenN-761062 RX2019-04-09
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
evenityBiologic Licensing Application2024-10-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postmenopausal osteoporosisEFO_0003854D015663—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M05: Drugs for treatment of bone diseases
— M05B: Drugs affecting bone structure and mineralization
— M05BX: Other drugs affecting bone structure and mineralization in atc
— M05BX06: Romosozumab
HCPCS
Code
Description
J3111
Injection, romosozumab-aqqg, 1 mg
Clinical
Clinical Trials
40 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteoporosisD010024EFO_0003882M81.0——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bone fracturesD050723EFO_0003931T14.8—1———1
Fracture healingD017102———1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRomosozumab
INNromosozumab
Description
Romosozumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2107874
ChEBI ID—
PubChem CID—
DrugBankDB11866
UNII ID3VHF2ZD92J (ChemIDplus, GSRS)
Target
Agency Approved
SOST
SOST
Organism
Homo sapiens
Gene name
SOST
Gene synonyms
NCBI Gene ID
50964
Protein name
sclerostin
Protein synonyms
Uniprot ID
Q9BQB4
Mouse ortholog
Sost (74499)
sclerostin (Q9D3L7)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Evenity – Amgen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,359 documents
View more details
Safety
Black-box Warning
Black-box warning for: Evenity
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
9,704 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use